Albireo Pharma, Inc. (NASDAQ:ALBO – Get Rating) – Stock analysts at Wedbush reduced their FY2022 EPS estimates for shares of Albireo Pharma in a research report issued on Wednesday, November 9th. Wedbush analyst A. Argyrides now expects that the biopharmaceutical company will post earnings per share of ($7.05) for the year, down from their previous estimate of ($6.40). Wedbush has a “Outperform” rating and a $61.00 price objective on the stock. The consensus estimate for Albireo Pharma’s current full-year earnings is ($7.89) per share. Wedbush also issued estimates for Albireo Pharma’s Q4 2022 earnings at ($0.90) EPS, Q1 2023 earnings at ($1.90) EPS, Q2 2023 earnings at ($1.85) EPS, Q3 2023 earnings at ($1.78) EPS, Q4 2023 earnings at ($1.86) EPS, FY2023 earnings at ($7.38) EPS, FY2024 earnings at ($6.87) EPS, FY2025 earnings at ($3.65) EPS and FY2026 earnings at $0.31 EPS.
Several other equities research analysts have also issued reports on ALBO. Guggenheim raised their price target on shares of Albireo Pharma to $59.00 in a research note on Thursday, October 13th. HC Wainwright raised their price target on shares of Albireo Pharma from $54.00 to $68.00 and gave the stock a “buy” rating in a research note on Wednesday, October 12th. StockNews.com started coverage on shares of Albireo Pharma in a research note on Wednesday, October 12th. They set a “sell” rating for the company. Finally, Robert W. Baird raised their price target on shares of Albireo Pharma from $43.00 to $55.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 12th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $60.75.
Albireo Pharma Stock Performance
Albireo Pharma (NASDAQ:ALBO – Get Rating) last posted its quarterly earnings data on Monday, August 15th. The biopharmaceutical company reported ($2.04) EPS for the quarter, missing the consensus estimate of ($1.58) by ($0.46). The firm had revenue of $8.21 million during the quarter, compared to analysts’ expectations of $9.42 million. Albireo Pharma had a negative net margin of 228.51% and a negative return on equity of 89.51%. During the same quarter last year, the business posted ($1.90) EPS.
Institutional Inflows and Outflows
Large investors have recently bought and sold shares of the company. Russell Investments Group Ltd. bought a new position in Albireo Pharma in the 1st quarter valued at $36,000. Allspring Global Investments Holdings LLC boosted its holdings in Albireo Pharma by 169.3% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,640 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 1,031 shares during the period. Quadrant Capital Group LLC boosted its holdings in Albireo Pharma by 4,397.4% in the 3rd quarter. Quadrant Capital Group LLC now owns 1,709 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 1,671 shares during the period. Barclays PLC boosted its holdings in Albireo Pharma by 131.6% in the 3rd quarter. Barclays PLC now owns 2,003 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 1,138 shares during the period. Finally, Lazard Asset Management LLC bought a new position in Albireo Pharma in the 1st quarter valued at $75,000. 91.34% of the stock is owned by institutional investors.
Insider Buying and Selling
In related news, major shareholder Perceptive Advisors Llc sold 179,132 shares of the firm’s stock in a transaction that occurred on Thursday, October 13th. The shares were sold at an average price of $22.01, for a total value of $3,942,695.32. Following the completion of the transaction, the insider now directly owns 1,939,723 shares of the company’s stock, valued at approximately $42,693,303.23. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last ninety days, insiders sold 324,745 shares of company stock valued at $7,364,552. Company insiders own 6.90% of the company’s stock.
About Albireo Pharma
Albireo Pharma, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases.
- Get a free copy of the StockNews.com research report on Albireo Pharma (ALBO)
- MarketBeat: Week in Review 11/7 – 11/11
- Oil Is a Compelling Reason The Sell-Off In Stocks Isn’t Over
- Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
- Six Flags is a Ride You Don’t Want to Get Stuck On
- Hanesbrands May be Signaling a Bad Week for Retail Stocks
Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.